We are creating some awesome events for you. Kindly bear with us.

HKSTP Partner Company and Healthcare Group to Push Forward Industry 4.0

Image Credits: HKSTP, Press Release
[social-share align="left" style="icon" size="m" template="18" counters="0" total_counter_pos="leftbig" buttons="linkedin,twitter,facebook,share"]

An end-to-end artificial intelligence (AI)-driven drug discovery and development company, under the Hong Kong Science and Technology Parks Corporation (HKSTP), and a leading innovation-driven international healthcare group in China announced that entered into a collaboration agreement to advance the discovery and development of drugs targeting several different targets globally through the use of AI technology.

This strategic collaboration includes an AI-driven drug discovery research and development (R&D) collaboration on four biological targets, as well as the co-development of the (AI)-driven drug discovery and development company’s QPCTL program. The company will receive a total upfront payment of US$13 million for the R&D collaboration projects and the co-development of the QPCTL program, potential milestone-based payments, and share commercialisation profits from the QPCTL program. In addition, Fosun Pharma will make an equity investment in the (AI)-driven drug discovery and development company.

The Founder and CEO of the drug discovery and development company stated that in partnering with the leading pharmaceutical company, the two will begin a new era of AI-powered end-to-end drug discovery and development as human-machine collaboration becomes the new normal in precision drug discovery and development.

The company previously demonstrated that AI can be used to discover novel targets and generate novel molecules that can be tested in humans in record time. Now, they are partnering with one of the leading scientific teams in the pharmaceutical industry to take this technology to the next level for the benefit of patients worldwide.

The Chairman and CEO of the leading innovation-driven international healthcare group stated that they are pleased to enter into a strategic collaboration with the drug discovery and development company. The healthcare group is committed to promoting innovative R&D and is oriented towards fulfilling unmet clinical needs and improving products’ accessibility.

They forward to working with the drug development company to leverage the technological and clinical development strengths of both companies, jointly improving the efficiency of innovative drug R&D, and benefiting more patients worldwide, he added.

The collaboration aims to combine the HKSTP partner company’s end-to-end AI-driven drug discovery platforms and the healthcare group’s clinical development and commercial expertise to discover and develop a portfolio of novel therapeutics.

Pursuant to the collaboration agreement, the company will take responsibility for delivering a preclinical candidate for the QPCTL program and advancing it to the IND stage, after which, the healthcare group will then conduct human clinical studies and co-develop the candidate globally. In parallel, the healthcare group’s R&D team will nominate four therapeutic targets to be assessed by the AI platform and R&D team, who are responsible for advancing drug candidates to the IND stage.

As part of the collaboration, the healthcare group will secure access to the company’s PandaOmics and Chemistry42 platforms to advance the healthcare group’s internal AI-powered discovery and development efforts.

The collaboration between the drug discovery and development company and the healthcare group create great synergies, bringing together leading lights in upstream AI-assisted drug discovery, and downstream clinical development. With such scale and depth of collaboration, we eagerly anticipate seeing what impacts it will bring clinically, according to the Head of the Institute for Translational Research of HKSTP.

[easy-social-share align="center" style="button" size="xxl" template="59" counters=0 noaffiliate="no" sidebar="no" popup="no" float="no" postfloat="no" topbar="no" bottombar="no" point="no" mobilebar="no" mobilebuttons="no" mobilepoint="no" facebook_text="Share on Facebook" linkedin_text="Share on LinkedIn" buttons="linkedin,facebook"]


Qlik’s vision is a data-literate world, where everyone can use data and analytics to improve decision-making and solve their most challenging problems. A private company, Qlik offers real-time data integration and analytics solutions, powered by Qlik Cloud, to close the gaps between data, insights and action. By transforming data into Active Intelligence, businesses can drive better decisions, improve revenue and profitability, and optimize customer relationships. Qlik serves more than 38,000 active customers in over 100 countries.


CTC Global Singapore, a premier end-to-end IT solutions provider, is a fully owned subsidiary of ITOCHU Techno-Solutions Corporation (CTC) and ITOCHU Corporation.

Since 1972, CTC has established itself as one of the country’s top IT solutions providers. With 50 years of experience, headed by an experienced management team and staffed by over 200 qualified IT professionals, we support organizations with integrated IT solutions expertise in Autonomous IT, Cyber Security, Digital Transformation, Enterprise Cloud Infrastructure, Workplace Modernization and Professional Services.

Well-known for our strengths in system integration and consultation, CTC Global proves to be the preferred IT outsourcing destination for organizations all over Singapore today.


Planview has one mission: to build the future of connected work. Our solutions enable organizations to connect the business from ideas to impact, empowering companies to accelerate the achievement of what matters most. Planview’s full spectrum of Portfolio Management and Work Management solutions creates an organizational focus on the strategic outcomes that matter and empowers teams to deliver their best work, no matter how they work. The comprehensive Planview platform and enterprise success model enables customers to deliver innovative, competitive products, services, and customer experiences. Headquartered in Austin, Texas, with locations around the world, Planview has more than 1,300 employees supporting 4,500 customers and 2.6 million users worldwide. For more information, visit www.planview.com.


SIRIM is a premier industrial research and technology organisation in Malaysia, wholly-owned by the Minister​ of Finance Incorporated. With over forty years of experience and expertise, SIRIM is mandated as the machinery for research and technology development, and the national champion of quality. SIRIM has always played a major role in the development of the country’s private sector. By tapping into our expertise and knowledge base, we focus on developing new technologies and improvements in the manufacturing, technology and services sectors. We nurture Small Medium Enterprises (SME) growth with solutions for technology penetration and upgrading, making it an ideal technology partner for SMEs.


HashiCorp provides infrastructure automation software for multi-cloud environments, enabling enterprises to unlock a common cloud operating model to provision, secure, connect, and run any application on any infrastructure. HashiCorp tools allow organizations to deliver applications faster by helping enterprises transition from manual processes and ITIL practices to self-service automation and DevOps practices. 


IBM is a leading global hybrid cloud and AI, and business services provider. We help clients in more than 175 countries capitalize on insights from their data, streamline business processes, reduce costs and gain the competitive edge in their industries. Nearly 3,000 government and corporate entities in critical infrastructure areas such as financial services, telecommunications and healthcare rely on IBM’s hybrid cloud platform and Red Hat OpenShift to affect their digital transformations quickly, efficiently and securely. IBM’s breakthrough innovations in AI, quantum computing, industry-specific cloud solutions and business services deliver open and flexible options to our clients. All of this is backed by IBM’s legendary commitment to trust, transparency, responsibility, inclusivity and service.